Detection of circulating melanoma cells in choroidal melanocytic lesions

Manuel F. Bande1*, Maria Santiago1, Laura Muinelo-Romay2, Maria Jose Blanco1, Purificacion Mera1, Carmela Capeans1, Maria Pardo3 and Antonio Piñeiro1

Abstract

Purpose: To detect and quantify circulating tumour cells (CTCs) in peripheral blood of patients with uveal melanoma primary non-metastatic tumours, and to analyze the possible relationship between CTCs and clinical risk factors.

Methods: Prospective study with two clinical groups: 4 patients diagnosed with choroidal nevus and 8 patients with choroidal melanoma prior to treatment. A single sample of 7.5 mL of peripheral blood was taken and the CTCs were isolated using a CellSearch system that captures positive cells for the CD146 antigen (MUC18).

Results: None of the patients with choroidal nevus showed CTCs in peripheral blood. More than one CTC/7.5 mL was detected in 50% of patients with choroidal melanoma prior to treatment. The higher level of CTC cells in peripheral blood (3/7.5 mL) was detected in the patient with the larger choroidal melanoma which also presented extrascle- ral extension and epithelioid pathology.

Conclusion: Performing an analysis with the CellSearch system allows to quantify the choroidal melanoma CTCs in peripheral blood. This finding highlights the potential usefulness of this technique to achieve the correct stratification and monitoring of the treatment.

Background

Despite the successful treatment of uveal melanoma (UM) primary tumors, patients remain at risk of developing metastases for more than 20 years after the initial diagnosis. In the Collaborative Ocular Melanoma Study (COMS), Kaplan–Meier analyses estimated that the 2-, 5-, and 10-year metastasis rates were 10, 25, and 34 %, respectively. However, only 0.24 % of patients exhibited detectable metastases at the time of diagnosis [1].

The CellSearch system (Veridex) was developed to identify and quantify CTCs in the peripheral blood by immunomagnetic isolation and immunohistochemical detection. This platform obtained the Food and Drug Administration (FDA) clearance for the CTC enumeration in patients with breast, colon, or prostate cancers [2, 3]. Despite that CellSearch system has been previously used in the detection of CTC in patients with metastatic uveal melanoma [4]; this technology has not been tested for non-metastatic/localized UM and choroidal nevi until now.

Our group investigated the possibility of detecting and quantifying CTCs using the semiautomatic CellSearch system in the peripheral blood of patients CTCs in the patients with primary/localized UM. Further, in this preliminary study we examined the relationship between the presence of CTCs, clinical parameters and disease-free survival.

Methods

12 Patients (8 UM and 4 choroidal nevus) diagnosed at the Ocular Oncology Unit (Servicio de Oftalmología, Santiago de Compostela, Spain) were included in the study after informed consent according to the Declaration of Helsinki. This study was also approved by the Comité Ético de Investigación Clínica de Galicia. Peripheral blood (7.5 mL, CellSave preservative tube, Veridex) was extracted at identical venipuncture points from each patient.

© 2015 Bande et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
cells were detected by the CellSearch system (Veridex, USA) as previously described [5, 6]. Briefly, melanoma cells were isolated with magnetic beads coated with anti-CD146 antibody. Then the CD146-expressing cells were stained with the fluorescent nucleic acid dye 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) and with a combination of fluorescent antibodies against high-molecular-weight melanoma-associated antigen (MEL), CD34 and CD45 to distinguish melanoma cells from leukocytes and endothelial cells (Fig. 1). Cell were considered CTCs when they have oval morphology and were positive for DAPI, MEL and negative for CD34 and CD45. Absence of metastatic melanoma at the time of blood sampling was confirmed by clinical evaluation, routine biochemistry and liver ultrasonography in all patients. The comparisons were done by using the Mann–Whitney U test. The correlations were done by Pearson’s correlation analysis.

Results
Among the eight patients with non-treated choroidal melanoma, 50 % displayed more than one CTC per 7.5 mL of blood. No significant correlation was shown between the CTC positivity and clinicopathological parameters, including the diameter of the largest tumor basal (LBD), the height of the tumor. The average patient follow-up was 25 months (min 16; max 27 months). The most important descriptive observation that emerged from this preliminary study was obtained from the largest choroidal melanoma, which demonstrated extrasceral extension (patient 1, Table 1). This patient presented the greatest number of CTCs and he was the only patient who presented metastatic liver disease at 12 months follow up. Moreover, four choroidal nevi (<2-mm height and <8-mm base) were tested, in which none CTCs were found.

Discussion
Circulating tumor cells (CTCs) are associated with the development of metastatic disease. In recent years, there has been considerable interest in the detection of disseminated tumor cells in the peripheral blood and bone marrow of patients with solid tumors. This interest is due in
part to the identification and quantification of CTCs by improved methods, such as immunomagnetic/immunohistochemistry [7–9] and reverse-transcriptase polymerase chain reaction (RT-PCR) [10]. Various studies have included PCR to quantify UM-associated mRNAs, such as tyrosinase and the melanoma antigen recognized by T-1 cells (MART-1/MLANA) [11]. These studies have not provided additional information beyond that of standard clinical approaches [12, 13]. This deficiency appears to be due to a lack of technique standardization, possible sample contamination, and the inability to directly quantify tumor cells.

On the other hand, we have not found a clear relationship between CTCs and tumor size or histological type in the studied patients. We also found that CTCs were not detected in the peripheral blood of 50% of patients with UM. This last point may be due to a better prognosis for these patients, but it may also owe to low detection sensitivity. The enrichment of the CellSearch System procedure with UM specific antibodies, in combination with anti-ME-PE, would significantly enhance the assay sensitivity.

This study has shown that the CellSearch system is appropriate to detect CTCs in patients with primary/localized UM. The ability to quantify and characterize CTCs in patients with UM is already a clinical reality in metastatic cutaneous melanoma. J Invest Dermatol. 2013;133:1582–90.

The correlation among the number of CTCs and the clinical factors such as tumor size and scleral invasion described in one of the UM patients in the present study is promising and suggests future applications of this technology. Additionally, this fact is supported by a very recent investigation describing the presence of CTCs in metastatic UM [4].

Conclusions
This finding demonstrates potential utility of CellSearch System for correct stratification, prognostic estimation, establishment of early therapies, and evaluation of response to different treatments in patients with UM.

Abbreviations
UM: uveal melanoma; CTCs: circulating tumor cells; RT-PCR: reverse-transcriptase polymerase chain reaction; MART-1/MLANA: tyrosinase and the melanoma antigen recognized 143 by T-1 cells; LBD: largest tumor basal; MLANA: melanoma-associated 144 antigen; DAPI: acid dye 4′,6-diamidino-2-phenylindole dihydrochloride; FDA: Food and Drug Administration.

Authors' contributions
Acquisition of data: MB, LM, MS. Analysis and interpretation of data: MB, LM, MP, AP. Drafting of manuscript: MB, MS, PA. Critical revision: CC, MJB, MP, AP. All authors read and approved the final manuscript.

Author details
1 Ocular Oncology Unit, Servizo de Oftalmoloxía, Complexo Hospitalario Universitario de Santiago, Universidade de Santiago de Compostela, Santiago de Compostela, Spain. 2 Liquid Biopsy Analysis Unit, Translational Medical Oncology Group, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain. 3 Grupo Obesidómica, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.

Acknowledgements
We acknowledge to the patients that participated in this study.

Compliance with ethical guidelines
The authors declare that they have no competing interests.

Received: 18 September 2014   Accepted: 7 September 2015

Published online: 17 September 2015

References
1. Collaborative Ocular Melanoma Study G. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma V: Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2009;124:1684–93.
2. Chen BT, Lobberg RD, Neeley CK, et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology. 2005;65:616–21.
3. Miller MC, Doyle GV, Testappan LW. Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010;2010:617431.
4. Bidard FC, Madic J, Mariani P, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer J Int du Cancer. 2014;134:1207–13.
5. Rao C, Bui T, Connelly M, et al. Circulating melanoma cells and survival in metastatic melanoma. Int J Oncol. 2011;38:755–60.
6. Khjoa L, Lorigan P, Zhou C, et al. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma. J Invest Dermatol. 2013;133:1582–90.
7. Tura A, Luke J, Merz H, et al. Identification of circulating melanoma cells in uveal melanoma patients by dual-marker immunoenrichment. Invest Ophthalmo Vis Sci. 2014;55:4395–404.
8. Mazzini C, Pinzani P, Salvianti F, et al. Circulating tumor cells detection and counting in uveal melanomas by a filtration-based method. Cancers. 2014;6:323–32.

9. Ulmer A, Beutel J, Susskind D, et al. Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:4469–74.

10. Schuster R, Bechrakis NE, Stroux A, et al. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma. Oncology. 2011;80:57–62.

11. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye. 2007;21:752–9.

12. Rodic S, Mihalciou C, Saleh RR. Detection methods of circulating tumor cells in cutaneous melanoma: a systematic review. Crit Rev Oncol Hematol. 2014;91:74–92.

13. Khoja L, Lorigan P, Dive C, Keilholz U, Fusi A. Circulating tumor cells as tumor biomarkers in melanoma: detection methods and clinical relevance. Ann Oncol. 2015;26:33–9.

14. Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010;5:e12517.